|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Genentech |
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00113217 |
Primary Objectives:
Secondary Objectives (Clinical):
Secondary Objectives (Preclinical):
Condition | Intervention | Phase |
Renal Cell Carcinoma Kidney Cancer |
Drug: Bevacizumab |
Phase II |
MedlinePlus related topics: | Cancer Kidney Cancer |
ChemIDplus related topics: | Bevacizumab |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMab VEGF (Bevacizumab) for Renal Cell Carcinoma |
Estimated Enrollment: | 50 |
Study Start Date: | February 2005 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
Bevacizumab
|
Drug: Bevacizumab
10 mg/kg IV on day 1 of each 14-day cycle.
|
Show Detailed Description |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Eric Jonasch, MD | 713-792-2830 |
United States, Texas | |||||
U.T.M.D. Anderson Cancer Center | Recruiting | ||||
Houston, Texas, United States, 77030 | |||||
Principal Investigator: Eric Jonasch, MD |
M.D. Anderson Cancer Center |
Genentech |
Principal Investigator: | Eric Jonasch, MD | U.T.M.D. Anderson Cancer Center |
Responsible Party: | U.T.M.D. Anderson Cancer Center ( Eric Jonasch, MD/Assistant Professor ) |
Study ID Numbers: | 2003-0982 |
First Received: | June 6, 2005 |
Last Updated: | April 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00113217 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|